At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
lapatinib +1 moredrug
Likely dose
lapatinib 1500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
In Brief
A Phase 2 clinical trial evaluating lapatinib and bevacizumab for Neoplasms, Breast. Completed, enrolled 52 participants across 9 sites.
Detailed Summary
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Breast
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedMar 2007
Primary CompletionJul 2008
Study CompletionJun 2020
TodayJul 2026
First PostedMar 8, 2007
Enrollment StartFeb 27, 2007
Primary CompletionJul 22, 2008
Study CompletionJun 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.3 years ago
Interventions
lapatinibdrug
1500 mg oral lapatinib (once daily)
bevacizumabdrug
10 mg/kg intravenous bevacizumab (every two weeks)